Zombie NIR™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye, Dead, Apoptosis
Ave. Rating
Submit a Review
Product Citations
publications
Zombie_NIR_Antibody_FC_062413
One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
  • Zombie_NIR_Antibody_FC_062413
    One day old C57BL/6 mouse splenocytes were stained with Zombie NIR™ and analyzed before fixation (purple) or after fixation and permeabilization (red). Cells alone, without Zombie NIR™ staining, are indicated in black.
See Zombie NIR™ spectral data
Cat # Size Price Quantity Check Availability Save
423105 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423106 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie NIR™ is an amine reactive fluorescent dye that is non-permeant to live cells, but permeant to the cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie NIR™ is a polar water soluble dye, providing red fluorescence, making it suitable for multi-color detection.

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie NIR™ Fixable Viability kit is composed of lyophilized Zombie NIR™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie NIR™ dye until fully dissolved. 100 tests = 1 vial of Zombie NIR™ + DMSO, 500 tests = 5 vials of Zombie NIR™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie NIR™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC - Quality tested

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

Excitation Laser
Red Laser (633 nm)
Application Notes

Zombie NIR™ dye is excited by the red laser and has fluorescence emission maximum at 746 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie NIR™ dye has similar emission to APC/Cyanine7.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie NIR™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie NIR™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie NIR™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie NIR™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie NIR™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie NIR™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie NIR™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie NIR™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie NIR™.
Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. McMaster SR, et al. 2015. PLoS One. 10:115725. PubMed
  2. Prado-Garcia H, et al. 2015. Anticancer Res.35:1529. PubMed
  3. Rodriguez-Rodriguez N, et al. 2015. J Immunol. 194:4207. PubMed
  4. Flies DB, et al. 2015. J Immunol. 194:5294. PubMed
Product Citations
  1. Kim MY, et al. 2021. JCI Insight. 6:. PubMed
  2. Martínez-Vélez N, et al. 2022. Mol Cancer Ther. 21:471. PubMed
  3. Baratchart E, et al. 2022. PLoS Comput Biol. 18:e1009839. PubMed
  4. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  5. Rosina M, et al. 2022. Cell Metab. 34:533. PubMed
  6. Hsu MA, et al. 2022. Cancer Immunol Immunother. :. PubMed
  7. Zheng J, et al. 2022. Front Pharmacol. 13:866228. PubMed
  8. Wu R, et al. 2022. J Dermatol. 49:432. PubMed
  9. Wang W, et al. 2022. Dev Cell. 57:228. PubMed
  10. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  11. Cautivo KM, et al. 2022. Immunity. 55:254. PubMed
  12. Kuloglu ZE, et al. 2022. Allergy. 77:2459. PubMed
  13. Bayley R, et al. 2022. Mol Cell. 82:1924. PubMed
  14. Rodriguez-Tirado C, et al. 2022. Cancer Res. 82:2313. PubMed
  15. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  16. Gideon HP, et al. 2022. Immunity. 55:827. PubMed
  17. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  18. Sudmeier LJ, et al. 2022. Cell Rep Med. 3:100620. PubMed
  19. Naseem MU, et al. 2022. J Gen Physiol. 154: . PubMed
  20. Vukovic N, et al. 2022. J Biol Chem. 298:102153. PubMed
  21. Berger G, et al. 2022. Proc Natl Acad Sci U S A. 119:e2111003119. PubMed
  22. Hsieh T, et al. 2022. Front Immunol. 13:901030. PubMed
  23. Werder RB, et al. 2022. Sci Adv. 8:eabo6566. PubMed
  24. Zhu Y, et al. 2022. Immunology. 167:576. PubMed
  25. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  26. Wang Z, et al. 2022. J Exp Med. 219: . PubMed
  27. Naranjo S, et al. 2022. Genes Dev. 36:936. PubMed
  28. Buckner CM, et al. 2022. Cell. 185:4333. PubMed
  29. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  30. Wang W, et al. 2022. Cell Rep. 41:111582. PubMed
  31. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  32. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  33. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  34. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  35. Naylor G, et al. 2022. Cancers (Basel). 14: . PubMed
  36. Ronning KE, et al. 2022. J Neuroinflammation. 19:299. PubMed
  37. Pleuger C, et al. 2022. Elife. 11: . PubMed
  38. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  39. Xu Q, et al. 2023. Nat Immunol. 24:186. PubMed
  40. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  41. Schepers M, et al. 2023. Brain Behav Immun. 109:1. PubMed
  42. Gauthier L, et al. 2023. Nat Biotechnol. :. PubMed
  43. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  44. Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed
  45. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  46. Rosain J, et al. 2023. Cell. 186:621. PubMed
  47. Ernst MPT, et al. 2023. Hemasphere. 7:e824. PubMed
  48. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  49. Dragan M, et al. 2022. J Invest Dermatol. 142:583. PubMed
  50. Parida PK, et al. 2022. Cell Metab. 34:90. PubMed
  51. Ma Y, et al. 2022. Am J Physiol Heart Circ Physiol. 322:H622. PubMed
  52. Salmon AJ, et al. 2022. Cancer Immunol Res. 10:597. PubMed
  53. Nelson LJ, et al. 2022. Cell Cycle. 21:1103. PubMed
  54. Kania AK, et al. 2022. J Immunol. 208:1873. PubMed
  55. Xu Y, et al. 2022. Bio Protoc. 12:e4354. PubMed
  56. McCafferty S, et al. 2022. Mol Ther. 30:2968. PubMed
  57. Liu Y, et al. 2022. Signal Transduct Target Ther. 7:347. PubMed
  58. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  59. Rad S M AH, et al. 2020. PLoS One. 15:e0232915. PubMed
  60. Headley M, et al. 2016. Nature. 531:513-517. PubMed
  61. Wang L, et al. 2020. Front Cell Dev Biol. 0.745138889. PubMed
  62. Iyer S, et al. 2021. Cancer Discov. 0.725. PubMed
  63. Pandey SP, et al. 2022. Cell Host Microbe. 30:1003. PubMed
  64. Knelson EH, et al. 2022. Cancer Immunol Res. 10:947. PubMed
  65. Sun Y, et al. 2022. STAR Protoc. 3:101479. PubMed
  66. Edwards KJ, et al. 2022. Cancer Immunol Res. 10:1084. PubMed
  67. Park G, et al. 2023. Photochem Photobiol. 99:850. PubMed
  68. Zhao Y, et al. 2022. J Neurosci. . PubMed
  69. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  70. Sauter M, et al. 2022. STAR Protoc. 3:101664. PubMed
  71. Terminel MN, et al. 2022. BMC Neurosci. 23:58. PubMed
  72. Tan GMY, et al. 2022. Cancers (Basel). 14:. PubMed
  73. Prochazka L, et al. 2022. Mol Syst Biol. 18:e10886. PubMed
  74. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  75. Han X, et al. 2022. Nutrients. 14:. PubMed
  76. Li Y, et al. 2023. Adv Mater. 35:e2208923. PubMed
  77. Schönberger K, et al. 2023. Anal Chem. 95:4325. PubMed
  78. Tschanz F, et al. 2021. Cancer Res Commun. 1:164. PubMed
  79. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  80. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  81. Muri J, et al. 2023. Nat Immunol. 24:604. PubMed
  82. Zhou P, et al. 2023. Immunity. 56:669. PubMed
  83. Ananya A, et al. 2023. Immun Ageing. 20:10. PubMed
  84. Pasqual G, et al. 2023. Methods Mol Biol. 2618:71. PubMed
  85. Luo X, et al. 2023. Methods Mol Biol. 2618:133. PubMed
  86. Jiang X, et al. 2023. J Clin Invest. 133:. PubMed
  87. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  88. Martins Nascentes Melo L, et al. 2023. J Immunother Cancer. 11:. PubMed
  89. Zhang YN, et al. 2023. Nat Commun. 14:1985. PubMed
  90. Onyshchenko K, et al. 2023. Nat Commun. 14:2087. PubMed
  91. Xu Z, et al. 2023. Cancers (Basel). 15:. PubMed
  92. Liu L, et al. 2023. J Exp Clin Cancer Res. 42:85. PubMed
  93. Glasner A, et al. 2023. Nat Immunol. 24:1020. PubMed
  94. Sugita M, et al. 2023. Cell Death Dis. 14:305. PubMed
  95. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  96. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  97. Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed
  98. Villalba N, et al. 2023. J Neuroinflammation. 20:127. PubMed
  99. Meckler JF, et al. 2023. Cancer Immunol Immunother. . PubMed
  100. Imai H, et al. 2023. iScience. 26:106822. PubMed
  101. Braun DJ, et al. 2023. PLoS One. 18:e0286495. PubMed
  102. Zhang TR, et al. 2023. Pharmaceuticals (Basel). 16:. PubMed
  103. Li JD, et al. 2023. Front Immunol. 14:1186393. PubMed
  104. Wu L, et al. 2023. Cell Res. . PubMed
  105. Cansever D, et al. 2023. Nat Immunol. . PubMed
  106. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  107. Hall, J. M., Caution, K. J., et al. 2025. Emerg Microbes Infect. 14(1),2547732. PubMed
  108. Wiese, M., Pessoa Rodrigues, C., et al. 2025. Life Sci Alliance. 8(12),0. PubMed
  109. Chen, F., Bradbury, M. S., et al. 2025. J Nanobiotechnology. 23(1),627. PubMed
  110. Liu, F., Tarannum, M., et al. 2025. Nat Commun. 16(1),8809. PubMed
  111. Jouve, C., Ruiz-Velasco, A., et al. 2025. Commun Biol. 8(1),1445. PubMed
  112. Ogunlusi, O., Sarkar, M., et al. 2025. Oncogene. 44(46),4491-4504. PubMed
  113. Yang, S., Cui, Y. H., et al. 2025. Nat Commun. 16(1),9946. PubMed
  114. Pascoe, R. D., Gubser, C., et al. 2025. EBioMedicine. 122(0),106004. PubMed
  115. Underwood, M. T., Devarapalli, V., et al. 2025. Noncoding RNA. 11(6),0. PubMed
  116. Yates, J. G. E., Chan, L., et al. 2025. Mol Ther Oncol. 33(4),201076. PubMed
  117. Weidling, H., Motta, E., et al. 2025. Front Immunol. 16(0),1645062. PubMed
  118. Jiang, X., Wang, M., et al. 2025. Mater Today Bio. 35(0),102593. PubMed
  119. Du, Z., Wan, P., et al. 2025. Nat Commun. 16(1),11168. PubMed
  120. Ajoge HO, et al. 2022. Viruses. 14:. PubMed
  121. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  122. Li Q, et al. 2022. Cell Rep. 40:111308. PubMed
  123. He C, et al. 2022. Sci Adv. 8:eabm4552. PubMed
  124. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  125. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
  126. Landry LG, et al. 2021. Bio Protoc. 11:e3883. PubMed
  127. Barros-Martins J, et al. 2021. Nat Med. 27:1525. PubMed
  128. Nordengrün M, et al. 2021. Front Immunol. 12:651060. PubMed
  129. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  130. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  131. Kallemeijn WW, et al. 2019. Cell Chem Biol. 26:892. PubMed
  132. Kollareddy M, et al. 2017. Cancer Lett. 10.1016/j.canlet.2017.05.027. PubMed
  133. Sheikh BN, et al. 2020. Nat Cell Biol. 22:828. PubMed
  134. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  135. Jiang C, et al. 2020. Int J Biol Sci. 2.802083333. PubMed
  136. Qiu J, et al. 2020. Cell Rep. 33:108465. PubMed
  137. Sagami S, et al. 2017. PLoS One. 10.1371/journal.pone.0169681. PubMed
  138. Lentucci C, et al. 2017. J Biol Chem. 292:2754-2772. PubMed
  139. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  140. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  141. Gibb D, et al. 2016. EBioMedicine. 9: 77-86. PubMed
  142. Sauter M, et al. 2022. iScience. 25:103677. PubMed
  143. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  144. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  145. Sneller MC, et al. 2022. Nature. 606:375. PubMed
  146. Hamminger P, et al. 2021. J Autoimmun. 119:102610. PubMed
  147. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  148. Schalbetter SM, et al. 2022. Sci Adv. 8:eabi6672. PubMed
  149. Abou-Hamad J, et al. 2022. iScience. 25:105524. PubMed
  150. Kilens S, et al. 2018. Nat Commun. 9:360. PubMed
  151. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  152. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  153. Karlen SJ, et al. 2018. J Neuroinflammation. 15:344. PubMed
  154. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  155. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  156. Jimenez-Duran G, et al. 2020. EBioMedicine. 61:103039. PubMed
  157. Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed
  158. Zou L, et al. 2022. Brain Behav Immun. 100:10. PubMed
  159. Son ET, et al. 2021. J Clin Invest. 131:. PubMed
  160. Majstrowicz K, et al. 2021. J Cell Sci. 134:. PubMed
  161. Daniel S, et al. 2021. Infect Immun. 89:e0016521. PubMed
  162. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  163. Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed
  164. Nagatake T, et al. 2022. Mucosal Immunol. 15:289. PubMed
  165. Watters JM, et al. 2021. Biochem Biophys Res Commun. 534:773. PubMed
  166. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
  167. Kodumudi KN, et al. 2019. Front Immunol. 10:1939. PubMed
  168. Liu HJ, et al. 2018. JCI Insight. 3. PubMed
  169. Agudelo M, et al. 2021. J Exp Med. :218. PubMed
  170. Gaebler C, et al. 2021. Nature. 639:591. PubMed
  171. Olingy C, et al. 2017. Sci Rep. 10.1038/s41598-017-00477-1. PubMed
  172. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
  173. Hering L, et al. 2021. Int J Mol Sci. 22:. PubMed
  174. Halim L, et al. 2022. Front Immunol. 13:836549. PubMed
  175. Hemkemeyer SA, et al. 2020. J Biol Chem. 296:100136. PubMed
  176. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  177. Agudelo M, et al. 2022. J Exp Med. 219:. PubMed
  178. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  179. Woodruff MC, et al. 2022. Nature. :. PubMed
  180. Patricio DO, et al. 2022. Front Immunol. 13:1042463. PubMed
  181. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  182. Verma M, et al. 2018. Cell Stem Cell. 23:530. PubMed
  183. Weisberg SP, et al. 2020. Cell Reports. 29(12):3916-3932.e5.. PubMed
  184. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  185. Bouffi C, et al. 2015. J Immunol. 195: 2683-2695. PubMed
  186. Higuchi T, et al. 2015. Cancer Immunol Res. 3: 1257 - 1268. PubMed
  187. Woodruff MC, et al. 2020. Nat Immunol. 1.920833333. PubMed
  188. Xu AQ, et al. 2020. Elife. 9:00. PubMed
  189. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  190. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  191. Guarnaccia AD, et al. 2021. Cell Rep. 108636:34. PubMed
  192. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  193. Mahmoud W, et al. 2021. Cell Tissue Res. Online ahead of print. PubMed
  194. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  195. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  196. Jenkins RW, et al. 2018. Cancer Discov. 8:196. PubMed
  197. Retamal‐Díaz A, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01523. PubMed
  198. Wlodarska M et al. 2017. Cell host & microbe. 22(1):25-37 . PubMed
  199. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  200. Akiyama H, et al. 2020. J Virol. . PubMed
  201. Sperber HS, et al. 2020. FASEB J. 14615:34. PubMed
  202. Moreau GB, et al. 2020. Am J Trop Med Hyg. 103:1215. PubMed
  203. Miller EB, et al. 2021. J Neuroinflammation. 18:235. PubMed
  204. Mills C, et al. 2022. Cells. 11:. PubMed
  205. Pettinato G, et al. 2021. Sci Adv. 7:. PubMed
  206. Godoy-Pacheco A, et al. 2022. Oncol Lett. 24:288. PubMed
  207. Rao X, et al. 2022. Cell Death Dis. 13:891. PubMed
  208. Simonneau M, et al. 2018. Oncotarget. 9:36457. PubMed
  209. Koizumi SI, et al. 2018. Nat Commun. 9:5344. PubMed
  210. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  211. Michaud D, et al. 2020. Cytokine. 125:154817. PubMed
  212. Adamik J, et al. 2022. Nat Commun. 13:5184. PubMed
  213. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  214. Zhang Z, et al. 2021. Acta Pharm Sin B. 11:1965. PubMed
  215. Mahadevan NR, et al. 2021. Cancer Discov. 11:1952. PubMed
  216. Alansary M, et al. 2021. Dent Traumatol. 37:90. PubMed
  217. Le X, et al. 2021. J Thorac Oncol. 16:583. PubMed
  218. Song D, et al. 2021. Sci Rep. 11:22966. PubMed
  219. Aires V, et al. 2021. Front Immunol. 12:684430. PubMed
  220. Choi JE, et al. 2021. Nat Metab. 3:182. PubMed
  221. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
  222. Lisk C, et al. 2020. Front Immunol. 1.329166667. PubMed
  223. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  224. Casella G, et al. 2017. Sci Rep. . 10.1038/s41598-017-16702-w. PubMed
  225. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  226. Aregger M, et al. 2020. Nat Metab. 0.429861111. PubMed
  227. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  228. PRADO-GARCIA H, et al. 2015. Anticancer Res. 35:1529. PubMed
  229. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  230. Thyrsted J, et al. 2021. iScience. 24:103300. PubMed
  231. Basu A, et al. 2021. Cancer Immunol Res. Online ahead of print. PubMed
  232. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  233. Nakajima T, et al. 2021. J Exp Med. 218:. PubMed
  234. Jie X, et al. 2022. J Immunother Cancer. 10:. PubMed
  235. Ferrer-Font L, et al. 2021. Curr Protoc. 1:e222. PubMed
  236. Li Y, et al. 2022. J Neuroinflammation. 19:261. PubMed
  237. Wang K, et al. 2018. Medicine (Baltimore). 97:e0710. PubMed
  238. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  239. Grandclaudon M, et al. 2019. Cell. 179:432. PubMed
  240. Steinbach K, et al. 2016. J Exp Med. 213: 1571 - 1587. PubMed
  241. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  242. Xie Z, et al. 2020. Light Sci Appl. 0.486805556. PubMed
  243. Wang Z, et al. 2021. bioRxiv. . PubMed
  244. English KG, et al. 2022. Biomedicines. 10:. PubMed
  245. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  246. Stinson WA, et al. 2022. JCI Insight. 7:. PubMed
  247. Kim S, et al. 2022. Redox Biol. 54:102347. PubMed
  248. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  249. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  250. Christopher GA, et al. 2021. Biomolecules. 12:. PubMed
  251. Cho A, et al. 2021. Nature. Online ahead of print. PubMed
  252. Clapes T, et al. 2021. Nat Cell Biol. 23:704. PubMed
  253. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  254. Woodruff M, et al. 2020. medRxiv. . PubMed
  255. McHugh D, et al. 2020. Life Sci Alliance. 3:00. PubMed
  256. Popay TM, et al. 2021. Elife. 10: . PubMed
  257. Wan G, et al. 2021. Sci Rep. 11:22121. PubMed
  258. Hills LB, et al. 2021. J Immunol. 206:89. PubMed
  259. Kuhn JA, et al. 2021. Elife. 10:. PubMed
  260. Bosnjak B, et al. 2021. Front Immunol. 12:772240. PubMed
  261. Xu Y, et al. 2021. Front Immunol. 12:666991. PubMed
  262. Zhang H, et al. 2021. Cell Rep. 36:109708. PubMed
  263. Zhu S, et al. 2022. J Oncol. 2022:8724933. PubMed
  264. Liu Y, et al. 2022. Front Oncol. 12:1037934. PubMed
  265. Espinoza J, et al. 2017. Oxidative Medicine and Cellular Longevity. 10.1155/2017/6781872. PubMed
  266. Pinder C, et al. 2017. J Immunol. 10.4049/jimmunol.1701253. PubMed
  267. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  268. Thompson EA, et al. 2021. Cell Rep. 108863:34. PubMed
  269. Lim JME, et al. 2022. Cell Rep Med. 3:100793. PubMed
  270. Vanekova L, et al. 2022. Methods Protoc. 5:. PubMed
  271. Elias G, et al. 2022. Elife. 11:. PubMed
  272. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  273. Nagatake T, et al. 2018. Int Immunol. 30:471. PubMed
  274. Ito Y, et al. 2018. Cell. 174:636. PubMed
  275. Scharer CD, et al. 2020. Nat Commun. 3989:11. PubMed
  276. Rodríguez-Rodríguez N, et al. 2015. J Immunol. 194:4207. PubMed
  277. Luo G, et al. 2021. Sci Rep. 11:7841. PubMed
  278. Braun DA, et al. 2021. Cancer Cell. 39:632. PubMed
  279. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
  280. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  281. Valestrand L, et al. 2022. Am J Pathol. . PubMed
  282. Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed
  283. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  284. Jalloh S, et al. 2022. PLoS Pathog. 18:e1010479. PubMed
  285. van Vloten JP, et al. 2019. Mol Ther Methods Clin Dev. 13:154. PubMed
  286. Akuffo AA, et al. 2018. J Biol Chem. 293:6187. PubMed
  287. Morganti JM, et al. 2019. J Neuroinflammation. 16:98. PubMed
  288. McGinnis CS, et al. 2019. Nat Methods. 1.096527778. PubMed
  289. Günther T, et al. 2019. PLoS Pathog. 15:e1007838. PubMed
  290. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  291. Meyrath M, et al. 2020. Nat Commun. 2.564583333. PubMed
  292. Ruibal P, et al. 2016. Nature. 533: 100-104. PubMed
  293. Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed
  294. Evgin L, et al. 2020. Nat Commun. 2.671527778. PubMed
  295. Hemkemeyer SA, et al. 2020. J Biol Chem. . PubMed
  296. Tajima M, et al. 2022. Curr Protoc. 2:e540. PubMed
  297. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  298. Lozano-Ojalvo D, et al. 2021. Cell Rep. 36:109570. PubMed
  299. Dieterle ME, et al. 2021. Elife. 10:. PubMed
  300. Sharma V, et al. 2021. ACR Open Rheumatol. 3:277. PubMed
  301. Clement CC, et al. 2021. Immunity. 54:721. PubMed
  302. Zhang YN, et al. 2021. Sci Adv. 7:eabj3107. PubMed
  303. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  304. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  305. Noort RJ, et al. 2021. Front Cell Dev Biol. 9:659397. PubMed
  306. Ramachandran P, et al. 2019. Nature. 575:512. PubMed
  307. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  308. Nagatake T, et al. 2018. J Allergy Clin Immunol. 142:470. PubMed
  309. Waight JD, et al. 2018. Cancer Cell. 33:1033. PubMed
  310. Soley BDS, et al. 2020. Br J Pharmacol. 177:3535. PubMed
  311. Lo CH, et al. 2021. Sci Rep. 6055:11. PubMed
  312. Salazar Y, et al. 2020. J Clin Invest. 130:3560. PubMed
  313. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
  314. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  315. Shim K, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.023. PubMed
  316. Tomić A, et al. 2016. PLoS Pathog. 12:e1006015. PubMed
  317. Filiano A, et al. 2016. Nature. 535:425-429. PubMed
  318. Armbruster N, et al. 2016. J Immunol. 196: 1284 - 1292. PubMed
  319. Wang Z, et al. 2021. Nature. 592:616. PubMed
  320. Ramos MIP, et al. 2021. Elife. 10:. PubMed
  321. Su Y, et al. 2021. Clin Cancer Res. :clincanres.2241.2021. PubMed
  322. Dudek M, et al. 2021. Nature. 592:444. PubMed
  323. Jacobsen H, et al. 2021. Nat Commun. 12:4957. PubMed
  324. Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed
  325. Janssen JJE, et al. 2022. Am J Physiol Endocrinol Metab. 322:E141. PubMed
  326. Wang Z, et al. 2022. J Exp Med. 219:. PubMed
  327. He Y, et al. 2022. Cells. 11:. PubMed
  328. Karanika S, et al. 2022. Front Immunol. 13:972266. PubMed
  329. Zhang Y, et al. 2018. Front Microbiol. 9:2967. PubMed
  330. Grajchen E, et al. 2020. J Neuroinflammation. 0.863888889. PubMed
  331. Cloarec R, et al. 2016. PLoS One. 11: 0160176. PubMed
  332. Rouleau N, et al. 2020. Immunohorizons. 0.695833333. PubMed
  333. Rizvi F, et al. 2021. Nat Commun. 0.925694444. PubMed
  334. Herland A, et al. 2020. Nat Biomed Eng. 421:4. PubMed
  335. Oherle K, et al. 2020. Immunity. 275:52. PubMed
  336. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  337. Tang JS, et al. 2022. Front Immunol. 13:946713. PubMed
  338. Wang Z, et al. 2021. Nature. 595:426. PubMed
  339. Mumby MJ, et al. 2021. J Virol. 95:e0058821. PubMed
  340. Chou TW, et al. 2021. Cell Death Dis. 12:756. PubMed
  341. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  342. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  343. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  344. Lien TS, et al. 2021. Front Immunol. 12:618577. PubMed
  345. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  346. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  347. Manuszak C, et al. 2020. J Biol Methods. 7:e131. PubMed
  348. McKenzie MD, et al. 2019. Cell Stem Cell. 25:258. PubMed
  349. Zischke J, et al. 2017. PLoS Pathogens. 13(6):e1006454. PubMed
  350. Luo L, et al. 2021. J Neuroinflammation. 18:27. PubMed
  351. Suzuki T, et al. 2017. Cell Rep. 18(8):2045-2057. PubMed
  352. McMaster S, et al. 2015. PLoS One. 10:115725. PubMed
  353. Donlan AN, et al. 2021. JCI Insight. 6: . PubMed
  354. Lisk C, et al. 2021. Front Immunol. 12:624197. PubMed
  355. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  356. Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed
  357. Zhang Y, et al. 2022. Mater Today Bio. 15:100317. PubMed
  358. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  359. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  360. Maas RR, et al. 2021. Nat Protoc. 16:4692. PubMed
  361. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  362. Mujal AM, et al. 2022. Cancer Immunol Res. 10:403. PubMed
  363. Chou DB, et al. 2022. Nat Commun. 13:6021. PubMed
  364. Daniels M, et al. 2017. Sci Rep.. 10.1038/s41598-017-17387-x. PubMed
  365. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  366. Flies D, et al. 2015. J Immunol. 194:5294. PubMed
  367. Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed
  368. Korin B, et al. 2020. Sleep. :43. PubMed
  369. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  370. Chakraborty A, et al. 2022. Methods Mol Biol. 2442:565. PubMed
  371. Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed
  372. Kiesel VA, et al. 2022. Front Oncol. 12:767479. PubMed
  373. Gutierrez-Prat N, et al. 2022. Life Sci Alliance. 5:. PubMed
  374. Viant C, et al. 2020. Cell. 183:1298. PubMed
  375. Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed
  376. Maller O, et al. 2020. Nat Mater. 20:548. PubMed
  377. Bryan AF, et al. 2020. Nucleic Acids Res. 48:2924. PubMed
  378. Sontheimer-Phelps A, et al. 2019. Cell Mol Gastroenterol Hepatol. 9:507. PubMed
  379. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  380. Eckert EC, et al. 2020. Mol Ther Oncolytics. 0.710416667. PubMed
  381. Gaebler C, et al. 2020. bioRxiv. . PubMed
  382. Shimada BK, et al. 2020. Immunohorizons. 0.55625. PubMed
  383. Jeffery H, et al. 2017. Clin Exp Immunol. 10.1111/cei.12940. PubMed
  384. Hosking M, Flynn C, Whitton J 2016. PLoS Pathog. 12: 1005861. PubMed
  385. Gangoso E, et al. 2021. Cell. 184:2454. PubMed
  386. Sibler E, et al. 2021. Cells. 10:. PubMed
  387. Qin J, et al. 2020. Cancer Immunol Res. 8:1426. PubMed
  388. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  389. Kastenschmidt JM, et al. 2021. Cell Rep. 35:108997. PubMed
  390. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  391. Sibler E, et al. 2022. Cancers (Basel). 14:. PubMed
  392. Spath S, et al. 2022. iScience. 25:104998. PubMed
  393. Farrand K, et al. 2022. Curr Protoc. 2:e482. PubMed
  394. Wachowska M, et al. 2020. Cancer Immunol Immunother. 69:1101. PubMed
  395. Chou DB, et al. 2020. Nat Biomed Eng. 0.440277778. PubMed
  396. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  397. Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
  398. Zhang N, et al. 2022. Front Immunol. 13:926368. PubMed
  399. Cho A, et al. 2022. J Exp Med. 219:. PubMed
  400. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  401. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  402. Zhou P, et al. 2022. Sci Transl Med. :eabi9215. PubMed
  403. Sauler M, et al. 2022. Nat Commun. 13:494. PubMed
  404. Guarnaccia AD, et al. 2021. STAR Protoc. 2:101000. PubMed
  405. Zhang L, et al. 2021. Mol Ther. 29:744. PubMed
  406. Gamradt S, et al. 2021. iScience. 24:103312. PubMed
  407. Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed
  408. Goddery EN, et al. 2021. Front Immunol. 12:726421. PubMed
  409. Xie Z, et al. 2020. Light Sci Appl. 9:161. PubMed
  410. Dar HH, et al. 2021. Redox Biol. 45:102045. PubMed
  411. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  412. Muchowicz A, et al. 2017. Eur J Cancer. 10.1016/j.ejca.2017.06.004. PubMed
  413. Clutton G, et al. 2016. Sci Rep. 6:30749. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 7    Revision Date: 12/18/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account